Restoring neuronal function with the brain's own small molecules
NeuResto’s focus is to target large unmet clinical needs in neurologic diseases, such as ischemic stroke, traumatic brain injury (TBI), and wet age-related macular degeneration (wet AMD), for which there are currently few therapeutic options. Additionally, the mechanisms underlying elovanoid's targeting of senescence genes, particular in the retina, are targets for novel therapies in aging diseases of the eye.
NeuResto’s technology is based on the discovery of Elovanoids in the laboratory of co-founder Nicolas Bazan, M.D., Ph.D.